« Previous
Next »
Titles
- Annual status report information and other submissions for postmarketing requirements and commitments: using forms FDA 3988 and FDA 3989 : guidance for industry1
- Breakthrough Devices Program: guidance for industry and Food and Drug Administration staff1
- CARES Act: experts identified safeguards to help selected HHS agencies protect against potential political interference : report to congressional requesters1
- Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products: guidance for industry1
- Enhanced drug distribution security at the package level under the Drug Supply Chain Security Act: guidance for industry1
- How do people make choices among marketplace plans?1
- Medicare Part B drugs: trends in spending and utilization, 2008-20211
- Medicare Part D enrollee out-of-pocket spending: recent trends and projected impacts of the Inflation Reduction Act1
- Medicare cognitive assessments: utilization tripled between 2018 and 2022, but challenges remain : report to congressional committees1
- National uninsured rate reaches an all-time low in early 2023 after the close of the ACA open enrollment period1
- Notifying FDA of a permanent discontinuance or interruption in manufacturing of a device under Section 506J of the FD&C Act: guidance for industry and Food and Drug Administration staff1
- Projected impacts for Asian Medicare enrollees1
- Projected impacts for Black Medicare enrollees1
- Projected impacts for Latino Medicare enrollees1
- The Bipartisan Safer Communities Act: where things stand on the Medicaid and CHIP provisions1
- Wholesale distributor verification requirement for saleable returned drug product and dispenser verification requirements when investigating a suspect or illegitimate product: compliance policies : guidance for industry1